

Firma	Akronym/Bezeichnung	Phase	Indikation	Beschreibung	Rekrutierung
<b>IPF STUDIEN</b>					
<b>Galapagos</b>	<b>ISABELA</b> GLPG1690-CL-304	III	Idiopathische Lungenfibrose	A Phase 3, randomized, double-blind, parallel-group, placebo-controlled, multi-center study to evaluate the efficacy and safety of two doses of GLPG1690 in addition to local standard of care for minimum 52 weeks in subjects with idiopathic pulmonary fibrosis.	<b>Aktiv</b>
<b>Nitto Denko</b>	<b>JUNIPER</b> ND-L02s-0201-005	II	Idiopathische Lungenfibrose	A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Biological Activity, and PK of ND-L02-s0201 in Subjects with Idiopathic Pulmonary Fibrosis (IPF)	<b>Aktiv</b>
<b>Novartis</b>	CVAY736X2207	II	Idiopathische Lungenfibrose	A subject-, investigator-, and sponsor-blinded, randomized, placebo-controlled, multicenter study to investigate efficacy, safety, and tolerability of VAY736 in patients with idiopathic pulmonary fibrosis	<b>Aktiv</b>
<b>FibroGen</b>	<b>ZEPHYRUS</b> FGCL-3019-091	III	Idiopathische Lungenfibrose	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects with Idiopathic Pulmonary Fibrosis (IPF)	<b>In Vorbereitung</b>
<b>Respivant</b>	<b>SCENIC</b> RVT1601-CC-04	IIb	Idiopathische Lungenfibrose  <b>Behandlung des Hustens</b>	Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study with Inhaled RVT-1601 for the Treatment of Persistent Cough in Patients with Idiopathic Pulmonary Fibrosis (IPF): SCENIC Trial	<b>Aktiv</b>
<b>Celgene/BMS</b>	CC-90001-IPF-001	II	Idiopathische Lungenfibrose	A Phase 2, 24-Week, Randomized, Double-blind, Placebo-controlled, multicenter Study, with an 80 week active Treatment Extension, to evaluate the efficacy and safety of CC-90001 in Subjects with IPF	<b>Aktiv</b>

<b>Nicht-IPF STUDIEN</b>					
<b>INBUILD-ON</b>	1199.248	III	PF-ILD	An open-label extension trial of the long term safety of nintedanib in patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD)	<b>Rekrutierung beendet</b>
<b>Alveolar Proteinose STUDIEN</b>					
<b>IMPALA</b>	IMPALA MOL PAPA 202 Extension	III	Alveolar Proteinose	An open-label,non-controlled, multicentre trial of inhaled Molgramotism in autoimmune pulmonary alveolar proteinosis patients	<b>Rekrutierung beendet</b>
<b>Sarkoidose STUDIEN</b>					
<b>Novartis</b>	CCMK389X2201	II	Sarkoidose	A subject and investigator blinded, randomized, placebocontrolled, repeat-dose, multicenter study to investigate efficacy, safety, and tolerability of CMK389 in patients with chronic pulmonary sarcoidosis.	<b>In Vorbereitung</b>